Table 3.

Observed testosterone, 17-β-estradiol, LH, and FSH concentrations and estimated changes during CIPII and SC insulin treatment.

	Testosterone (nmol/L)		17-β-estradiol (pmol/L)		LH (U/L)		FSH (U/L)
	CIPII	SC insulin	CIPII	SC insulin	CIPII	SC insulin	CIPII	SC insulin
Males (n=10)
0 months	22.9 [16.1, 27.7]	23.4 [17.5, 26.4]	79.0 [71.7, 148.7]	80.2 [57.5, 125.6]	5.9 [3.1, 6.6]	5.3 [3.6, 7.7]	3.8 [2.5, 6.6]	4.8 [3.3, 8.3]
3 months	16.5 [16.0, 19.0]	23.5 [17.7, 27.5]	60.2 [48.0, 111.4]	74.6 [73.4, 123.6]	3.5 [2.5, 6.1]	6.6 [3.8, 7.2]	3.2 [2.1, 6.6]	4.6 [2.7, 8.0]
6 months	20.8 [13.5, 24.2]	19.8 [18.1, 24.9]	73.3 [51.8, 132.0]	74.2 [60.6, 132.5]	7.0 [4.2, 8.6]	5.1 [4.6, 6.7]	6.9 [3.0, 10.3]	4.1 [2.5, 6.7]
Difference during treatment	−8.3 (−14.4, −2.2)*	−2.3 (−8.7, 4.0)	−14.2 (−41.0, 12.7)	9.7 (−17.5, 36.9)	2.2 (−0.8, 5.2)	−0.1 (−2.9, 2.6)	0.4 (−9.1, 9.9)	−0.5 (−1.2, 0.2)
Difference between treatment groups	−6.0 (−14.7, 2.8)		–23.9 (–61.9, 14.2)		2.3 (−1.8, 6.4)		1.2 (0.1, 2.2)*
Females (n=10)
0 months	1.1 [0.5, 1.7]	0.9 [0.4, 1.0]
3 months	0.4 [0.2, 1.2]	0.6 [0.3, 1.2]
6 months	0.6 [0.2, 1.2]	0.8 [0.3, 1.1]
Difference during treatment	−0.1 (−0.4, 0.1)	−0.1 (−0.5, 0.3)
Difference between treatment groups	−0.1 (−0.5, 0.4)

Data are shown as median [IQR] and estimated mean changes (95% CI)) in nmol/L for SHBG and testosterone, in pmol/L for 17-β-estradiol and in U/L for LH and FSH.

*P<0.05.